$ARDT

Ardent Health, Inc.

No enriched coverage for $ARDT in the last 7 days.

No SEC Form 4 filings for $ARDT in the last 30 days.

Med

Weather hit patient volumes, but Ardent kept its 2026 forecast

Ardent Health, Inc. reported its first-quarter 2026 results, showing a 7.0% increase in total revenue year-over-year to $1.60 billion and a 26.3% rise in Adjusted EBITDA to $124 million. Despite a slight decrease in admissions due to severe weather and a lighter respiratory season, the company reaffirmed its full-year 2026 financial guidance. The strong performance was attributed to disciplined execution, effective cost management, and the positive impact of its IMPACT program.

ARDT INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Ardent Health (ARDT) Investors of Securities Class Action Deadline on March 9, 2026

Faruqi & Faruqi, LLP is reminding investors of Ardent Health (ARDT) that the deadline to seek lead plaintiff status in a federal securities class action lawsuit is March 9, 2026. The lawsuit alleges that Ardent Health and its executives made misleading statements and failed to disclose information regarding the company's accounts receivable. This follows a significant drop in Ardent's stock price after the company announced a $43 million reduction in revenue due to accounting changes and a $54 million increase in professional liability reserves in Q3 2025.

ARDT Investors Have Opportunity to Lead Ardent Health, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm has announced a class action lawsuit against Ardent Health, Inc. (NYSE: ARDT) for alleged securities fraud, encouraging investors who purchased securities between July 18, 2024, and November 12, 2025, to contact the firm. The lawsuit claims Ardent made misleading statements regarding its accounting practices for accounts receivable and failed to maintain adequate professional malpractice liability insurance. Investors have until March 9, 2026, to participate as lead plaintiffs.